NeoGenomics (NEO)

• Market cap: $1.27B
• 1 day: -2.89%
• 5 days: -35.65%
• 1 month: -32.67%
• 3 months: -56.82%
• 6 months: -52.63%
• Year to date: -61.25%
• 1 year: -54.09%
• 5 years: -76.63%
• 10 years: 41.06%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Employees: 2,200

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

789% more call options, than puts

Call options by funds: $15.6M | Put options by funds: $1.76M

11% more capital invested

Capital invested by funds: $1.82B [Q3] → $2.02B (+$202M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

0.82% less ownership

Funds ownership: 96.34% [Q3] → 95.52% (-0.82%) [Q4]

6% less funds holding

Funds holding: 267 [Q3] → 250 (-17) [Q4]

18% less repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 95

35% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 34

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8.50 33% upside
• Avg. target: $12.30 92% upside
• High target: $18 182% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target	56% upside $10	Buy Maintained	30 Apr 2025
Leerink Partners Puneet Souda 20% 1-year accuracy 1 / 5 met price target	41% upside $9	Market Perform Downgraded	30 Apr 2025
Needham Mike Matson 36% 1-year accuracy 44 / 121 met price target	33% upside $8.50	Buy Maintained	29 Apr 2025
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target	182% upside $18	Overweight Maintained	26 Feb 2025
B of A Securities Derik De Bruin 35% 1-year accuracy 7 / 20 met price target	150% upside $16	Neutral Maintained	19 Feb 2025